Source: Reuters FRANKFURT (Reuters) - Bayer has agreed to sell its established prescription dermatology brands to Denmark’s Leo Pharma, as the German drugmaker focuses on integrating seed maker Monsanto and on bolstering its drug development pipeline. The portfolio to be sold includes prescription skin creams against acne, fungal skin infections…...
Sienna Biopharmaceuticals Successfully Completes Maximal Use Safety Study Of SNA-120 In Patients With Itch Associated With Psoriasis
Source: Sienna Biopharmaceuticals Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today announced results from a Phase 1b maximal use (MUse) pharmacokinetic (PK) and safety study of SNA-120 (pegcantratinib), a Phase 2b drug candidate being evaluated as a topical, nonsteroidal therapy to treat itch (pruritus) associated with psoriasis.…...
Dermavant inks $330M deal for GSK’s phase 3-ready psoriasis drug
Source: FierceBiotech A new CSO isn't all Dermavant got from GlaxoSmithKline: The Roivant unit has picked up the rights to the British drugmaker's dermatology drug tapinarof in a deal worth up to £250 million ($330 million). The asset is poised to enter phase 3 in psoriasis and atopic dermatitis and is also…...
Cassiopea Announces Very Positive Top-Line Phase 3 Results For Winlevi® (Clascoterone) Cream In Treating Acne
Source: Cassiopea Lainate, Italy – 10 July 2018 - Cassiopea SpA (SIX: SKIN), a clinical-stage specialty pharmaceutical company focused on developing and commercializing innovative and differentiated medical dermatology products, today announced that top line results from two pivotal phase 3 clinical trials for its topical anti-androgen Winlevi® cream 1% (Clascoterone) demonstrated…...